GeoVax to Present Clinical Data on Multi-Antigen COVID-19 Vaccine for Immunocompromised Patients

GeoVax Labs, Inc. announced that its Chief Medical Officer and clinical collaborators will present data highlighting the cross-variant antibody and robust cellular immune responses induced by the Company's next-generation COVID-19 vaccine (GEO-CM04S1) in immunocompromised patients with hematologic malignancies at two upcoming scientific meetings in September. The data will be presented at the 6th ESCMID Conference on Vaccines: From Development to Real-World Clinical Practice and Global Health in Lisbon, Portugal, where more information on the conference can be found at https://www.escmid.org/congress-events/6th-escmid-conference-on-vaccines.

Additionally, data will be presented at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) in Krakow, Poland, with conference details available at https://www.iwcll.org/events/xxi-iwcll-12-15-september-2025-krakow-poland/. The presentations will focus on GEO-CM04S1's performance as a multi-antigen COVID-19 vaccine specifically designed for immunocompromised individuals, including patients with chronic lymphocytic leukemia (CLL).

The clinical data demonstrates that the MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia compared with mRNA-based vaccines, based on initial results from a Phase II randomized study. This finding is particularly significant because current authorized COVID-19 vaccines have shown insufficient protection for immunocompromised patient populations, leaving them vulnerable to severe COVID-19 outcomes.

GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers, as a booster vaccine in patients with chronic lymphocytic leukemia, and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. The vaccine's ability to induce cross-variant antibody responses addresses the ongoing challenge of COVID-19 variants evading immunity from previous infections or vaccinations.

The development of effective vaccines for immunocompromised populations represents a critical advancement in public health, as these patients face significantly higher risks of severe illness and mortality from COVID-19. The robust cellular immune responses observed with GEO-CM04S1 suggest potential for longer-lasting protection and better defense against emerging variants, which could transform COVID-19 management for vulnerable patient groups worldwide.